Skip to main content

KAZIA THERAPEUTICS LTD

corporate_fare Company Profile

KAZIA THERAPEUTICS LTD

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed KZIA - Latest Insights

KZIA
Apr 27, 2026, 8:30 AM EDT
Filing Type: 6-K
Importance Score:
7
KZIA
Apr 15, 2026, 8:30 AM EDT
Filing Type: 6-K
Importance Score:
8
KZIA
Apr 15, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
KZIA
Apr 13, 2026, 5:26 PM EDT
Filing Type: 424B3
Importance Score:
7
KZIA
Apr 13, 2026, 5:25 PM EDT
Filing Type: 424B3
Importance Score:
8
KZIA
Apr 13, 2026, 5:25 PM EDT
Filing Type: 424B3
Importance Score:
7
KZIA
Apr 13, 2026, 5:25 PM EDT
Filing Type: 424B3
Importance Score:
9
KZIA
Apr 13, 2026, 5:24 PM EDT
Filing Type: 6-K
Importance Score:
8
KZIA
Mar 31, 2026, 7:00 PM EDT
Filing Type: 424B3
Importance Score:
7
KZIA
Mar 31, 2026, 4:56 PM EDT
Filing Type: 6-K
Importance Score:
7
KZIA
Mar 19, 2026, 5:19 PM EDT
Filing Type: 424B3
Importance Score:
9
KZIA
Mar 19, 2026, 5:17 PM EDT
Filing Type: 424B3
Importance Score:
9
KZIA
Mar 19, 2026, 5:09 PM EDT
Filing Type: 6-K
Importance Score:
9
KZIA
Jan 27, 2026, 8:10 AM EST
Filing Type: 6-K
Importance Score:
8